Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Diabetes

Therapy for gestational diabetes mellitus—time for a change?

Nature Reviews Endocrinology volume 11, pages 327–328 (2015)Cite this article

Subjects

For >30 years, insulin has been the drug of choice for the medical treatment of gestational diabetes mellitus. However, the use of oral hypoglycaemic agents has increased during the past 1–2 decades, so a recent comparison of treatment with glibenclamide, metformin or insulin in women with gestational diabetes mellitus is highly relevant.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Jiwani, A. et al. Gestational diabetes mellitus: results from a survey of country prevalence and practices. J. Matern. Fetal Neonatal Med. 25, 600–610 (2012).

    Article  Google Scholar 

  2. Balsells, M. et al. Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis. BMJ http://dx.doi.org/10.1136/bmj.h102.

  3. HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. N. Engl. J. Med. 358, 1991–2002 (2008).

  4. Crowther, C. A. et al. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N. Engl. J. Med. 352, 2477–2486 (2005).

    Article  CAS  Google Scholar 

  5. Landon, M. B. et al. A multicenter, randomized trial of treatment for mild gestational diabetes. N. Engl. J. Med. 361, 1339–1348 (2009).

    Article  CAS  Google Scholar 

  6. Clausen, T. D. et al. High prevalence of type 2 diabetes and pre-diabetes in adult offspring of women with gestational diabetes mellitus or type 1 diabetes: the role of intrauterine hyperglycemia. Diabetes Care 31, 340–346 (2008).

    Article  Google Scholar 

  7. Rowan, J. A. et al. Metformin versus insulin for the treatment of gestational diabetes. N. Engl. J. Med. 358, 2003–2015 (2008).

    Article  CAS  Google Scholar 

  8. Rowan, J. A. et al. Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition at 2 years of age. Diabetes Care 34, 2279–2284 (2011).

    Article  CAS  Google Scholar 

  9. Carlsen, S. M., Martinussen, M. P. & Vanky, E. Metformin's effect on first-year weight gain: a follow-up study. Pediatrics 130, e1222–e1226 (2012).

    Article  Google Scholar 

  10. Rø, T. B., Ludvigsen, H. V., Carlsen, S. M. & Vanky, E. Growth, body composition and metabolic profile of 8-year-old children exposed to metformin in utero. Scand. J. Clin. Lab Invest. 72, 570–575 (2012).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Obstetrics and Endocrinology, Center for Pregnant Women with Diabetes 4001, Rigshospitalet, The Institute of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 9, Copenhagen, DK-2100, Denmark

    Peter Damm & Elisabeth R. Mathiesen

Authors
  1. Peter Damm
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elisabeth R. Mathiesen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter Damm.

Ethics declarations

Competing interests

P.D. and E.R.M. are participating in a multicentre, multinational observational study of the use of injectable hypoglycaemic agents in pregnant women with type 1 diabetes mellitus and type 2 diabetes mellitus in collaboration with Novo Nordisk. P.D. has received fees for giving talks for Novo Nordisk. E.R.M. has received fees for giving talks for Novo Nordisk, Sanofi-Aventis and Eli Lilly, E.R.M. has received a research grant from The Novo Nordisk Foundation.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Damm, P., Mathiesen, E. Therapy for gestational diabetes mellitus—time for a change?. Nat Rev Endocrinol 11, 327–328 (2015). https://doi.org/10.1038/nrendo.2015.54

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrendo.2015.54

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing